Navigation Links
PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer Study
Date:3/18/2009

STOCKHOLM, Sweden, March 18 /PRNewswire/ --

- Attn: Healthcare Editors

Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published online 1700 hours CET 18 March (NEJM, Online First*). ERSPC is the world's largest prostate cancer screening study and provides robust, independently- audited evidence, for the first time, of the effect of screening on prostate cancer mortality.

The study commenced in the early 1990s involving eight countries - Belgium, Finland, France, Italy, Netherlands, Spain, Sweden and Switzerland - with an overall follow-up of up to 12 years. Participants totalled 182,000 but then narrowed down to 162,000 men in seven countries, aged 55-69; only those who had not been screened could take part. The findings are being unveiled at the annual European Urology Congress in Stockholm, Sweden (17 - 21 March 2009).

By initially screening men 55 to 69 years with the PSA marker and offering regular follow up, this led to an increase in early detection. Deaths due to metastasized disease were then reduced. Exact data showed that on average for every 1,408 men screened, 48 had cancer diagnosed and received treatment, resulting in saving one life. Screening took place on average every four years with a mean follow-up over nine years. The cut-off value was a PSA level of 3.0 ng/ml or more. Men with this reading were then offered a biopsy.

Prof Fritz Schroder, international coordinator of the ERSPC study explained: "The study shows that PSA screening delivers a 20% reduction in mortality from prostate cancer. This provides decision makers on screening policies with important new data on the effectiveness of PSA testing in preventing deaths.

"However, The ERSPC is also near to completing additional studies on quality of life and cost-effectiveness and these must be assessed before making a decision about the appropriateness of a national prostate screening policy."

Worldwide, prostate cancer is the second leading cause of cancer death. Separate ERSPC findings already confirm that approximately 30% of detected cancers actually have non-aggressive features and are 'indolent' or slow growing. This overdiagnosis is an unavoidable effect from all cancer screening procedures. With prostate cancer, a new, more conservative form of monitoring, 'Active Surveillance', might be an important method to help avoid early invasive treatment (www.erspc.org).

*http://content.nejm.org/cgi/content/full/NEJMoa0810084


'/>"/>
SOURCE ERSPC (European Randomized Study of Screening for Prostate Cancer)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
2. Lenetix Launches Screening Study of New Down Syndrome Test
3. Breakthrough in Prenatal Screening for Down Syndrome
4. ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options
5. Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study
6. FDA Reviewing Biomoda Submission for Cancer Screening Study
7. Task Force Recommends Screening for Hearing Loss in All Newborns
8. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
9. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Lung Cancer Alliance Commends NCCN on Screening Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... , April 27, 2016 ... reach USD 2.06 billion by 2022, according to ... Increasing consumer awareness towards a healthy lifestyle is ... seven years.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... coupled with rising health treatment expenditure has urged ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... the open availability of a new CDISC standard, Clinical Trial Registry (CTR) ... trials. This innovative standard will make it possible to build applications that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one ... a leading force in the fight to reduce tobacco use and its deadly ... can help reduce tobacco use. The initiative brings together two organizations committed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader ... biomechatronics, technology that marries human physiology with electromechanics. He continues that work as Director ... Founder of BionX , a leader in the field of prosthetic devices. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline is one of ... in the Healthy Ageing category, Cognizin® is being considered for this prestigious honor ... can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a ...
(Date:4/28/2016)... ... ... Card reminds us that May is National Stroke Awareness Month. According to the Centers ... in the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes ... old. A stroke is when blood flow to the brain is blocked or when ...
Breaking Medicine News(10 mins):